Clinical Trial

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.
Protocol Amendment History 2 changes
critical Trial completed 2026-06-23
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-29
Trial Details
NCT Number NCT06970301
Lead Sponsor UCB Biopharma SRL
Conditions Healthy Study Participants
Enrollment 32 participants
Start Date 2025-04-28
Primary Completion 2026-05-29 (estimated)
Study Completion 2026-05-29 (estimated)
Updated on ClinicalTrials.gov 2026-06-22